PubMed · 2003 · 114 citations · 29 references
MedicineOncologyPharmacologyDrug DiscoveryMetastasisMolecular OncologyCancer Cell SignalingMetastatic Signaling PathwaysReceptor Tyrosine Kinase SignalingTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsKinase InhibitorsMet InhibitorsMet Receptor Tyrosine KinaseSelective Tyrosine Kinase InhibitorsSmall Molecule Tyrosine Kinase InhibitorsTherapeutic Tyrosine Kinase InhibitorsTyrosine Kinase InhibitionTyrosine Kinase Inhibitor Therapy
The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, mediates various cellular responses on activation with its ligand, including proliferation, survival, motility, invasion, and tubular morphogenesis. Met expression is frequently up-regulated in sarcomas and carcinomas. Experimental evidence suggests that Met activation correlates with poor clinical outcome and the likelihood of metastasis. Therefore, inhibitors of Met tyrosine kinase may be useful for the treatment of a wide variety of cancers that have spread from the primary site. We have discovered potent and selective pyrrole-indolinone Met kinase inhibitors and characterized them for their ability to inhibit HGF/SF-induced cellular responses in vitro. These compounds inhibit HGF/SF-induced receptor phosphorylation in a dose-dependent manner. They also inhibit the HGF/SF-induced motility and invasion of epithelial and carcinoma cells. Therefore, these compounds represent a class of prototype small molecules that selectively inhibit the Met kinase and could lead to identification of compounds with potential therapeutic utility in treatment of cancers.
29
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility
M. G. P. Stoker, Ermanno Gherardi, M. Benjamin Perryman et al. · Nature · 1987 · 1.3K citations
Michael Jeffers, Sing Rong, George F. Vande Woude · Molecular and Cellular Biology · 1996 · 313 citations · Full text